Serum salusin-α and salusin-β levels in patients with Behcet’s disease
Behcet’s disease (BD) is a chronic, relapsing, systemic vasculitis of unknown etiology. There is an increased predisposition to insulin resistance and metabolic syndrome (MetS) in BD patients.
The aim of this study was to determine serum salusin-α and salusin-β levels in BD patients and healthy controls and to investigate their association with MetS.
Patients and Methods
Twenty-five BD patients and 25 healthy controls were included in the study. Salusin-α and salusin-β levels were measured in blood samples using ELISA. In addition, BD patients and healthy controls were evaluated in terms of MetS.
The mean serum salusin-α level in BD patients was significantly lower compared to healthy controls (p = 0.03), whereas the mean serum salusin-β level in BD patients was significantly higher compared to healthy controls (p = 0.03). The mean serum salusin-α level was significantly lower in BD patients with MetS compared to BD patients without MetS (p = 0.04).
Serum salusin-α level (an anti-atherogenic molecule) was lower, while serum salusin-β level (a pro-atherogenic molecule) was higher in BD patients. We consider that the decrease in salusin-α and the increase in salusin-β levels contribute to the development of MetS.
Key wordsBehcet’s Disease salusin-α salusin-β metabolic syndrome insulin resistance
Unable to display preview. Download preview PDF.
- 5.Gül A. Behcet’s disease: an update on the pathogenesis. Clin Exp Rheumatol 2001; 19: 6–12.Google Scholar
- 12.International Study Group for Behcet’s Disease: Criteria for diagnosis of Behcet’s disease. Lancet 1990; 335: 1078–80.Google Scholar